Pheast Therapeutics

Today we welcome Aditi Bapat, Ph.D., as a Scientist on our Discovery Team! One of the fun science facts she shared with us is that elephants have 20 copies of the tumor suppressor gene p53 (as opposed to humans and other mammals that normally only have one copy). This may be why elephants rarely get cancer. Her curiosity is a great asset and her motivation to make a difference to the lives of others aligns so well with the Pheast mission. Welcome, Aditi! 🚀 #TeamPheast #oncology #cancer #macrophages #PheastMode 

We're pleased to introduce the newest member of #TeamPheast, Payal Gala, as Manager, Drug Product and Formulation. With her expertise in process and product development of protein-based biologics, Payal will help us manufacture our macrophage-directed antibody drug candidate for the clinic. Welcome, Payal! 🚀 

Today’s press release shares the first preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor. Read the release here: https://lnkd.in/gEyPSwN8 If you are at #PEGS2024 in #Boston, don’t miss our talk at 1:15 pm ET titled, “Engineering a Therapeutic Monoclonal Antibody Targeting CD24, a Macrophage Checkpoint.” #PEGS24 #CD24 #oncology #cancer #macrophages #antibodies #checkpointinhibitor #macrophage 

We’re excited to share at #PEGSummit our first presentation of data for PHST001, our lead anti-CD24 antibody drug that is designed to block a key macrophage "don't eat me" signal on cancer cells. PHST001 can powerfully reactivate an anti-cancer immune response and drive therapeutic efficacy. Pheast's Senior Director of Protein Sciences, John Burg, Ph.D., will be presenting these data describing the discovery and optimization of our drug candidate against this emerging #immunotherapy target. Join him online or in person in #Boston on Monday, May 13th at 1:10 pm ET for his talk titled, “Engineering a Therapeutic Monoclonal Antibody Targeting CD24, a Macrophage Checkpoint.” See the full agenda and register here: https://lnkd.in/giDSmHAb #PEGS2024 #PEGS24 #CD24 #oncology #cancer #macrophages #antibodies

We're pleased to introduce the newest member of #TeamPheast, Thomas Lopez, as Senior Scientist. Tom brings a wealth of experience in biochemistry and antibody engineering to help us develop novel macrophage-directed cancer therapeutics. 

It’s International Women's Day, and we celebrate the incredible women who inspire inclusion every day, including our Director of Translational Sciences, Jen Cao, who co-chairs the Association for Women in Science’s Palo Alto Mentorship Program. Not only is Jen a brilliant scientist, but she’s committed to empowering other #WomenInSTEM. If you would like to follow her example and become a mentor, check out The AWIS Palo Alto Mentoring Program website: https://lnkd.in/g98bJtGV #InternationalWomensDay #IWD2024 #WD2024 #InspireInclusion #WomenInScience #WomensHistoryMonth #Culture #LeadByExample #PheastMode #MentorshipMatters

Connect with people that inspire you! This is one of four top tips from Jen Cao, our Director of Translational Science when asked: what advice would you give to young women who are considering pursuing a #CareerinSTEM? Thanks Jen for sharing this great advice for #IDWGS! #WomeninSTEM #WomeninScience

New Year, New Space! We’ve doubled the size of our lab, and we are excited to have a bit more space for our Discovery,  and Protein Sciences, CMC and Project Management teams. Thanks to the Pheast team for a successful move and ribbon cutting. #PheastMode 

In this Q&A with Drug Target Review, our CSO and cofounder Dr. Roy Maute reveals more about our promising drug candidate and why CD24 is such an exciting target in cancer immunotherapy as a potent activator of anti-tumour immunity. Read the interview here: https://lnkd.in/gFRXqREP 

Thank you to the Pheast team for a wonderful year! We are so proud of all we’ve accomplished together, and we look forward to 2024. Wishing everyone a happy and healthy holiday!